On August3, 2017, Juno Therapeutics, Inc. ("Juno") announced its financial results for the quarter ended June 30, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing, regardless of any general incorporation language in any such filing, unless Juno expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.

(d) Exhibits

Juno Therapeutics, Inc. Exhibit
EX-99.1 2 ex-991xq22017.htm EXHIBIT 99.1 Exhibit Exhibit 99.1JUNO THERAPEUTICS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS- Presented promising JCAR017 data in NHL with 66% (21/32) overall response and 50% (16/32) complete response at three months in core group moving to pivotal trial — 2% (1/44) experienced severe CRS and 18% (8/44) experienced severe NT — Completed JCAR017 commercial manufacturing process lock — Eleven product candidates in clinical trials against eight different targets — 2017 cash burn guidance reaffirmed — Strong cash position of $801.8 million - - Conference call today at 5:00 p.m. Eastern Time -SEATTLE – August 3,…
To view the full exhibit click here

About Juno Therapeutics, Inc. (NASDAQ:JUNO)

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171) and JCAR020: MUC-16/IL-12. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.